William L Lowe1, Denise M Scholtens1, Lynn P Lowe1, Alan Kuang1, Michael Nodzenski1, Octavious Talbot1, Patrick M Catalano2, Barbara Linder3, Wendy J Brickman1,4, Peter Clayton5, Chaicharn Deerochanawong6, Jill Hamilton7, Jami L Josefson1,4, Michele Lashley8, Jean M Lawrence9, Yael Lebenthal10, Ronald Ma11, Michael Maresh12, David McCance13, Wing Hung Tam11, David A Sacks9, Alan R Dyer1, Boyd E Metzger1. 1. Northwestern University Feinberg School of Medicine, Chicago, Illinois. 2. MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio. 3. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland. 4. Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois. 5. Royal Manchester Children's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, School of Medical Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, England. 6. Rajavithi Hospital, Bangkok, Thailand. 7. Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. 8. Queen Elizabeth Hospital, School of Clinical Medicine and Research, University of the West Indies, Barbados. 9. Kaiser Permanente of Southern California, Pasadena. 10. Jesse Z. and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 11. Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China. 12. St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, England. 13. Royal Victoria Hospital, Belfast, Ireland.
Abstract
Importance: The sequelae of gestational diabetes (GD) by contemporary criteria that diagnose approximately twice as many women as previously used criteria are unclear. Objective: To examine associations of GD with maternal glucose metabolism and childhood adiposity 10 to 14 years' postpartum. Design, Setting, and Participants: The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study established associations of glucose levels during pregnancy with perinatal outcomes and the follow-up study evaluated the long-term outcomes (4697 mothers and 4832 children; study visits occurred between February 13, 2013, and December 13, 2016). Exposures: Gestational diabetes was defined post hoc using criteria from the International Association of Diabetes and Pregnancy Study Groups consisting of 1 or more of the following 75-g oral glucose tolerance test results (fasting plasma glucose ≥92 mg/dL; 1-hour plasma glucose level ≥180 mg/dL; 2-hour plasma glucose level ≥153 mg/dL). Main Outcomes and Measures: Primary maternal outcome: a disorder of glucose metabolism (composite of type 2 diabetes or prediabetes). Primary outcome for children: being overweight or obese; secondary outcomes: obesity, body fat percentage, waist circumference, and sum of skinfolds (>85th percentile for latter 3 outcomes). Results: The analytic cohort included 4697 mothers (mean [SD] age, 41.7 [5.7] years) and 4832 children (mean [SD] age, 11.4 [1.2] years; 51.0% male). The median duration of follow-up was 11.4 years. The criteria for GD were met by 14.3% (672/4697) of mothers overall and by 14.1% (683/4832) of mothers of participating children. Among mothers with GD, 52.2% (346/663) developed a disorder of glucose metabolism vs 20.1% (791/3946) of mothers without GD (odds ratio [OR], 3.44 [95% CI, 2.85 to 4.14]; risk difference [RD], 25.7% [95% CI, 21.7% to 29.7%]). Among children of mothers with GD, 39.5% (269/681) were overweight or obese and 19.1% (130/681) were obese vs 28.6% (1172/4094) and 9.9% (405/4094), respectively, for children of mothers without GD. Adjusted for maternal body mass index during pregnancy, the OR was 1.21 (95% CI, 1.00 to 1.46) for children who were overweight or obese and the RD was 3.7% (95% CI, -0.16% to 7.5%); the OR was 1.58 (95% CI, 1.24 to 2.01) for children who were obese and the RD was 5.0% (95% CI, 2.0% to 8.0%); the OR was 1.35 (95% CI, 1.08 to 1.68) for body fat percentage and the RD was 4.2% (95% CI, 0.9% to 7.4%); the OR was 1.34 (95% CI, 1.08 to 1.67) for waist circumference and the RD was 4.1% (95% CI, 0.8% to 7.3%); and the OR was 1.57 (95% CI, 1.27 to 1.95) for sum of skinfolds and the RD was 6.5% (95% CI, 3.1% to 9.9%). Conclusions and Relevance: Among women with GD identified by contemporary criteria compared with those without it, GD was significantly associated with a higher maternal risk for a disorder of glucose metabolism during long-term follow-up after pregnancy. Among children of mothers with GD vs those without it, the difference in childhood overweight or obesity defined by body mass index cutoffs was not statistically significant; however, additional measures of childhood adiposity may be relevant in interpreting the study findings.
Importance: The sequelae of gestational diabetes (GD) by contemporary criteria that diagnose approximately twice as many women as previously used criteria are unclear. Objective: To examine associations of GD with maternal glucose metabolism and childhood adiposity 10 to 14 years' postpartum. Design, Setting, and Participants: The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study established associations of glucose levels during pregnancy with perinatal outcomes and the follow-up study evaluated the long-term outcomes (4697 mothers and 4832 children; study visits occurred between February 13, 2013, and December 13, 2016). Exposures: Gestational diabetes was defined post hoc using criteria from the International Association of Diabetes and Pregnancy Study Groups consisting of 1 or more of the following 75-g oral glucose tolerance test results (fasting plasma glucose ≥92 mg/dL; 1-hour plasma glucose level ≥180 mg/dL; 2-hour plasma glucose level ≥153 mg/dL). Main Outcomes and Measures: Primary maternal outcome: a disorder of glucose metabolism (composite of type 2 diabetes or prediabetes). Primary outcome for children: being overweight or obese; secondary outcomes: obesity, body fat percentage, waist circumference, and sum of skinfolds (>85th percentile for latter 3 outcomes). Results: The analytic cohort included 4697 mothers (mean [SD] age, 41.7 [5.7] years) and 4832 children (mean [SD] age, 11.4 [1.2] years; 51.0% male). The median duration of follow-up was 11.4 years. The criteria for GD were met by 14.3% (672/4697) of mothers overall and by 14.1% (683/4832) of mothers of participating children. Among mothers with GD, 52.2% (346/663) developed a disorder of glucose metabolism vs 20.1% (791/3946) of mothers without GD (odds ratio [OR], 3.44 [95% CI, 2.85 to 4.14]; risk difference [RD], 25.7% [95% CI, 21.7% to 29.7%]). Among children of mothers with GD, 39.5% (269/681) were overweight or obese and 19.1% (130/681) were obese vs 28.6% (1172/4094) and 9.9% (405/4094), respectively, for children of mothers without GD. Adjusted for maternal body mass index during pregnancy, the OR was 1.21 (95% CI, 1.00 to 1.46) for children who were overweight or obese and the RD was 3.7% (95% CI, -0.16% to 7.5%); the OR was 1.58 (95% CI, 1.24 to 2.01) for children who were obese and the RD was 5.0% (95% CI, 2.0% to 8.0%); the OR was 1.35 (95% CI, 1.08 to 1.68) for body fat percentage and the RD was 4.2% (95% CI, 0.9% to 7.4%); the OR was 1.34 (95% CI, 1.08 to 1.67) for waist circumference and the RD was 4.1% (95% CI, 0.8% to 7.3%); and the OR was 1.57 (95% CI, 1.27 to 1.95) for sum of skinfolds and the RD was 6.5% (95% CI, 3.1% to 9.9%). Conclusions and Relevance: Among women with GD identified by contemporary criteria compared with those without it, GD was significantly associated with a higher maternal risk for a disorder of glucose metabolism during long-term follow-up after pregnancy. Among children of mothers with GD vs those without it, the difference in childhood overweight or obesity defined by body mass index cutoffs was not statistically significant; however, additional measures of childhood adiposity may be relevant in interpreting the study findings.
Authors: Matthew W Gillman; Sheryl Rifas-Shiman; Catherine S Berkey; Alison E Field; Graham A Colditz Journal: Pediatrics Date: 2003-03 Impact factor: 7.124
Authors: Patrick M Catalano; Kristen Farrell; Alicia Thomas; Larraine Huston-Presley; Patricia Mencin; Sylvie Hauguel de Mouzon; Saeid B Amini Journal: Am J Clin Nutr Date: 2009-09-16 Impact factor: 7.045
Authors: Denise M Scholtens; James R Bain; Anna C Reisetter; Michael J Muehlbauer; Michael Nodzenski; Robert D Stevens; Olga Ilkayeva; Lynn P Lowe; Boyd E Metzger; Christopher B Newgard; William L Lowe Journal: Diabetes Date: 2016-04-05 Impact factor: 9.461
Authors: Christine W Hockett; Kylie K Harrall; Brianna F Moore; Anne P Starling; Anna Bellatorre; Katherine A Sauder; Wei Perng; Ann Scherzinger; Kavita Garg; Brandy M Ringham; Deborah H Glueck; Dana Dabelea Journal: Diabetologia Date: 2019-08-23 Impact factor: 10.122
Authors: Jami L Josefson; Patrick M Catalano; William L Lowe; Denise M Scholtens; Alan Kuang; Alan R Dyer; Lynn P Lowe; Boyd E Metzger Journal: J Clin Endocrinol Metab Date: 2020-07-01 Impact factor: 5.958
Authors: M L Erickson; J T Mey; C L Axelrod; D Paul; L Gordesky; K Russell; H Barkoukis; P O'Tierney-Ginn; R A Fielding; J P Kirwan; P M Catalano Journal: Contemp Clin Trials Date: 2020-05-08 Impact factor: 2.226
Authors: Katrien Benhalima; Anaïs De Landtsheer; Paul Van Crombrugge; Carolien Moyson; Johan Verhaeghe; Hilde Verlaenen; Chris Vercammen; Toon Maes; Els Dufraimont; Christophe De Block; Yves Jacquemyn; Annouschka Laenen; Roland Devlieger; Caro Minschart; Chantal Mathieu Journal: Acta Diabetol Date: 2020-11-20 Impact factor: 4.280